In vitro and in vivo binding of toremifene and its metabolites in rat uterus
- PMID: 2142232
- DOI: 10.1016/0022-4731(90)90004-c
In vitro and in vivo binding of toremifene and its metabolites in rat uterus
Abstract
The in vitro binding affinities of toremifene (TOR), 4-hydroxy toremifene (4-OH-TOR) and several other metabolites for the rat uterine cytosolic estrogen receptor were compared with those of tamoxifen (TAM) and 4-hydroxy tamoxifen (4-OH-TAM). Only small differences were observed and the binding affinities of both 4-hydroxy metabolites were similar to that of estradiol (E2). Uterine uptake and subcellular distribution of [3H]TOR and [3H]TAM were then compared at 1, 8 and 72 h after administration to castrated rats. The uptake and retention of both antiestrogens were similar at all times. In each case the amount of nuclear bound radioactivity declined to low levels at 8 and 72 h but the ratios of 4-OH-TAM/TAM and 4-OH-TOR/TOR determined by HPLC analysis increased dramatically at 72 h. The level of radioactivity in both plasma and uterine cytosol at 72 h was significantly higher following [3H]TAM administration. However, most of the radioactivity appeared to be in a conjugated form since it was not extractable with solvent. Finally, the ability of prior administration of each antiestrogen (100 mg/kg) to block uterine [3H]estradiol uptake was examined at 3 and 7 days. It was found that uterine wet weights were higher than control one week after administration of both compounds. Prior administration of TOR increased nuclear uptake of [3H]E2 whereas TAM had no effect. The results of these experiments suggest that toremifene and tamoxifen have very similar in vitro and in vivo binding properties but differences in metabolism exist that may be important.
Similar articles
-
Binding of estrogen and antiestrogen in uterine cell nuclei: in vivo autoradiographic studies.J Steroid Biochem. 1988 Oct;31(4A):405-9. doi: 10.1016/0022-4731(88)90308-1. J Steroid Biochem. 1988. PMID: 3172774
-
Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.J Steroid Biochem Mol Biol. 1998 Feb;64(3-4):199-205. doi: 10.1016/s0960-0760(97)00192-1. J Steroid Biochem Mol Biol. 1998. PMID: 9605415
-
Comparison of the physicochemical properties of uterine nuclear estrogen receptors bound to estradiol or 4-hydroxytamoxifen.Endocrinology. 1986 Aug;119(2):904-15. doi: 10.1210/endo-119-2-904. Endocrinology. 1986. PMID: 3732150
-
Review of the pharmacological properties of toremifene.J Steroid Biochem. 1990 Jun 22;36(3):191-5. doi: 10.1016/0022-4731(90)90003-b. J Steroid Biochem. 1990. PMID: 2142231 Review.
-
Preclinical studies with toremifene as an antitumor agent.Breast Cancer Res Treat. 1990 Aug;16 Suppl:S9-17. doi: 10.1007/BF01807139. Breast Cancer Res Treat. 1990. PMID: 2149286 Review.
Cited by
-
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.Clin Pharmacokinet. 1992 May;22(5):327-58. doi: 10.2165/00003088-199222050-00002. Clin Pharmacokinet. 1992. PMID: 1505141 Review.
-
Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.Drug Saf. 2001;24(14):1039-53. doi: 10.2165/00002018-200124140-00003. Drug Saf. 2001. PMID: 11735660 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources